Lupin Launches 40 Mg Duloxetine DR Capsules in the US

New Delhi: Drug major Lupin has launched generic anti-depressant drug Duloxetine in 40 mg strength in the US market.
  Lupin had earlier launched Duloxetine HCl DR Capsules in strengths of 20 mg, 30 mg and 60 mg in December, 2013, which are the generic equivalent of Eli Lilly & Company's Cymbalta DR capsules in similar strengths.
  Lupin is now the only generic manufacturer to offer all Duloxetine dosage strengths - the 20 mg, 30 mg, 60 mg, and now the newest 40 mg, Lupin said in a statement.
  Lupin Pharmaceuticals, Inc, the US-based subsidiary of the company has launched its Duloxetine 40 mg delayed-release (DR) capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength in the US market.
  Duloxetine delayed-release capsule are used to treat depression and anxiety disorder.
  "Lupin is excited to bring this new strength to market, as it adds to the currently-available dosing options for greater flexibility of treatment," the Mumbai-based firm said.
  According to IMS MAT June 2015 data, Cymbalta DR capsules in strengths of 20 mg, 30 mg and 60 mg had annual sales of around $1.05 billion in the US.
  Lupin shares today ended at Rs 1,863.10 apiece on the BSE, down 0.94 per cent from previous close.